Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon

Experimental and Molecular Pathology

Volumn 80, Issue 3, 2006, Pages 252-261

  Kilinc, Mehmet O ^a   Mukundan, Lata ^b   Yolcu, Esma S ^a,b   Singh, Narendra P ^a   Suttles, Jill ^b   Shirwan, Haval ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Adjuvant; CD40L; Chimeric immunostimulatory proteins; Immunomodulation; Streptavidin

Indexed keywords

CD40 LIGAND; CHAPERONE; CHEMOKINE; CHIMERIC PROTEIN; CYTOKINE; OLIGOMER; STREPTAVIDIN; TETRAMER; POLYMER;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENATURATION; DENDRITIC CELL; DISSOCIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MONOCYTE; MOUSE; NONHUMAN; PROTEIN STABILITY; TEMPERATURE; UPREGULATION; ANIMAL; CHEMISTRY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOLOGY; SYNTHESIS; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; B-LYMPHOCYTES; BLOTTING, WESTERN; CD40 LIGAND; CELL LINE, TUMOR; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MICE; MOLECULAR CHAPERONES; MONOCYTES; POLYMERS; STREPTAVIDIN; TRANSFECTION;

EID: 33745542998     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2005.12.004     Document Type: Article

References (65)

1. Armitage R.J., Fanslow W.C., Strockbine L., Sato T.A., Clifford K.N., Macduff B.M., Anderson D.M., Gimpel S.D., Davis-Smith T., and Maliszewski C.R. Molecular and biological characterization of a murine ligand for CD40. Nature 357 (1992) 80-82
2. Askenasy N., Yolcu E.S., Wang Z., and Shirwan H. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 107 (2003) 1525-1531
3. Baccam M., and Bishop G.A. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur. J. Immunol. 29 (1999) 3855-3866
4. Bachmann M.F., and Kopf M. Balancing protective immunity and immunopathology. Curr. Opin. Immunol. 14 (2002) 413-419
5. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
6. Bishop G.A., and Hostager B.S. Molecular mechanisms of CD40 signaling. Arch. Immunol. Ther. Exp. 49 (2001) 129-137
7. Borrebaeck C.K., Malmborg A.C., and Ohlin M. Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?. Immunol. Today 14 (1993) 477-479
8. + T cell memory. Science 297 (2002) 2060-2063
9. Briones J., Timmerman J., and Levy R. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res. 62 (2002) 3195-3199
10. Carbone E., Ruggiero G., Terrazzano G., Palomba C., Manzo C., Fontana S., Spits H., Karre K., and Zappacosta S. A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J. Exp. Med. 185 (1997) 2053-2060
11. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., and Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184 (1996) 747-752
12. Challa A., Pound J.D., Armitage R.J., and Gordon J. Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells. Allergy 54 (1999) 576-583
13. Clark L.B., Foy T.M., and Noelle R.J. CD40 and its ligand. Adv. Immunol. 63 (1996) 43-78
14. Clemons-Miller A.R., Cox G.W., Suttles J., and Stout R.D. LPS stimulation of TNF-receptor deficient macrophages: a differential role for TNF-alpha autocrine signaling in the induction of cytokine and nitric oxide production. Immunobiology 202 (2000) 477-492
15. Contin C., Pitard V., Itai T., Nagata S., Moreau J.F., and chanet-Merville J. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J. Biol. Chem. 278 (2003) 32801-32809
16. Coussaert T., Volkel A.R., Noolandi J., and Gast A.P. Streptavidin tetramerization and 2D crystallization: a mean-field approach. Biophys. J. 80 (2001) 2004-2010
17. Dilloo D., Brown M., Roskrow M., Zhong W., Holladay M., Holden W., and Brenner M. CD40 ligand induces an antileukemia immune response in vivo. Blood 90 (1997) 1927-1933
18. Foy T.M., Aruffo A., Bajorath J., Buhlmann J.E., and Noelle R.J. Immune regulation by CD40 and its ligand GP39. Annu. Rev. Immunol. 14 (1996) 591-617
19. French R.R., Chan H.T., Tutt A.L., and Glennie M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5 (1999) 548-553
20. Funakoshi S., Longo D.L., Beckwith M., Conley D.K., Tsarfaty G., Tsarfaty I., Armitage R.J., Fanslow W.C., Spriggs M.K., and Murphy W.J. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83 (1994) 2787-2794
21. Gauchat J.F., Henchoz S., Fattah D., Mazzei G., Aubry J.P., Jomotte T., Dash L., Page K., Solari R., and Aldebert D. CD40 ligand is functionally expressed on human eosinophils. Eur. J. Immunol. 25 (1995) 863-865
22. Ghamande S., Hylander B.L., Oflazoglu E., Lele S., Fanslow W., and Repasky E.A. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 61 (2001) 7556-7562
23. Grassme H., Bock J., Kun J., and Gulbins E. Clustering of CD40 ligand is required to form a functional contact with CD40. J. Biol. Chem. 277 (2002) 30289-30299
24. Haswell L.E., Glennie M.J., and Al Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur. J. Immunol. 31 (2001) 3094-3100
25. Holler N., Tardivel A., Kovacsovics-Bankowski M., Hertig S., Gaide O., Martinon F., Tinel A., Deperthes D., Calderara S., Schulthess T., Engel J., Schneider P., and Tschopp J. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 23 (2003) 1428-1440
26. Honeychurch J., Glennie M.J., Johnson P.W., and Illidge T.M. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 102 (2003) 1449-1457
27. Hostager B.S., Hsing Y., Harms D.E., and Bishop G.A. Different CD40-mediated signaling events require distinct CD40 structural features. J. Immunol. 157 (1996) 1047-1053
28. Howland K.C., Ausubel L.J., London C.A., and Abbas A.K. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J. Immunol. 164 (2000) 4465-4470
29. Hsu Y.M., Lucci J., Su L., Ehrenfels B., Garber E., and Thomas D. Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J. Biol. Chem. 272 (1997) 911-915
30. Huang H.I., Wu P.Y., Teo C.Y., Chen M.N., Chen Y.C., Silin D., and Tao M.H. Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand. Int. J. Cancer 108 (2004) 696-703
31. Khazaeli M.B., Conry R.M., and LoBuglio A.F. Human immune response to monoclonal antibodies. J. Immunother. 15 (1994) 42-52
32. Koch F., Stanzl U., Jennewein P., Janke K., Heufler C., Kampgen E., Romani N., and Schuler G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184 (1996) 741-746
33. Lehr R.V., Elefante L.C., Kikly K.K., O'Brien S.P., and Kirkpatrick R.B. A modified metal-ion affinity chromatography procedure for the purification of histidine-tagged recombinant proteins expressed in Drosophila S2 cells. Protein Expression Purif. 19 (2000) 362-368
34. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2001) 487-501
35. Lukin K., Cosyns M., Mitchell T., Saffry M., and Hayward A. Eradication of Cryptosporidium parvum infection by mice with ovalbumin-specific T cells. Infect. Immun. 68 (2000) 2663-2670
36. Mackey M.F., Barth Jr. R.J., and Noelle R.J. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J. Leukocyte Biol. 63 (1998) 418-428
37. Mackey M.F., Wang Z., Eichelberg K., and Germain R.N. Distinct contributions of different CD40 TRAF binding sites to CD154-induced dendritic cell maturation and IL-12 secretion. Eur. J. Immunol. 33 (2003) 779-789
38. Mazzei G.J., Edgerton M.D., Losberger C., Lecoanet-Henchoz S., Graber P., Durandy A., Gauchat J.F., Bernard A., Allet B., and Bonnefoy J.Y. Recombinant soluble trimeric CD40 ligand is biologically active. J. Biol. Chem. 270 (1995) 7025-7028
39. Melief C.J., Van Der Burg S.H., Toes R.E., Ossendorp F., and Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188 (2002) 177-182
40. Morel Y., Truneh A., Sweet R.W., Olive D., and Costello R.T. The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J. Immunol. 167 (2001) 2479-2486
41. Morris A.E., Remmele Jr. R.L., Klinke R., Macduff B.M., Fanslow W.C., and Armitage R.J. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J. Biol. Chem. 274 (1999) 418-423
42. + T cells correlates with Th1/Th2 phenotype. J. Immunol. 160 (1998) 5347-5354
43. Nakamura I., Kajino K., Bamba H., Itoh F., Takikita M., and Ogasawara K. Phenotypic stability of mature dendritic cells tuned by TLR or CD40 to control the efficiency of cytotoxic T cell priming. Microbiol. Immunol. 48 (2004) 211-219
44. Onaitis M.W., Kalady M.F., Emani S., Abdel-Wahab Z., Tyler D.S., and Pruitt S.K. CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. Surgery 134 (2003) 300-305
45. Pound J.D., Challa A., Holder M.J., Armitage R.J., Dower S.K., Fanslow W.C., Kikutani H., Paulie S., Gregory C.D., and Gordon J. Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells. Int. Immunol. 11 (1999) 11-20
46. Pullen S.S., Labadia M.E., Ingraham R.H., McWhirter S.M., Everdeen D.S., Alber T., Crute J.J., and Kehry M.R. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 38 (1999) 10168-10177
47. Qureshi M.H., Yeung J.C., Wu S.C., and Wong S.L. Development and characterization of a series of soluble tetrameric and monomeric streptavidin muteins with differential biotin binding affinities. J. Biol. Chem. 276 (2001) 46422-46428
48. Reznik G.O., Vajda S., Smith C.L., Cantor C.R., and Sano T. Streptavidins with intersubunit crosslinks have enhanced stability. Nat. Biotechnol. 14 (1996) 1007-1011
49. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., and Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187 (1998) 1205-1213
50. Singh N.P., Yolcu E.S., Taylor D.D., Gercel-Taylor C., Metzinger D.S., Dreisbach S.K., and Shirwan H. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res. 63 (2003) 4067-4073
51. Stout R.D., and Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol. Today 17 (1996) 487-492
52. Stout R.D., Suttles J., Xu J., Grewal I.S., and Flavell R.A. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156 (1996) 8-11
53. Thomas W.D., Smith M.J., Si Z., and Hersey P. Expression of the co-stimulatory molecule CD40 on melanoma cells. Int. J. Cancer 68 (1996) 795-801
54. Tian L., Noelle R.J., and Lawrence D.A. Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur. J. Immunol. 25 (1995) 306-309
55. Todryk S.M., Tutt A.L., Green M.H., Smallwood J.A., Halanek N., Dalgleish A.G., and Glennie M.J. CD40 ligation for immunotherapy of solid tumours. J. Immunol. Methods 248 (2001) 139-147
56. Tong A.W., and Stone M.J. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 10 (2003) 1-13
57. Van Kooten C., and Banchereau J. CD40-CD40 ligand. J. Leukocyte Biol. 67 (2000) 2-17
58. + T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur. J. Immunol. 24 (1994) 3148-3154
59. Wagner Jr. D.H., Vaitaitis G., Sanderson R., Poulin M., Dobbs C., and Haskins K. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3782-3787
60. Wagner A.H., Guldenzoph B., Lienenluke B., and Hecker M. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler., Thromb., Vasc. Biol. 24 (2004) 714-720
61. Wahl L.M., Katona I.M., Wilder R.L., Winter C.C., Haraoui B., Scher I., and Wahl S.M. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis. Cell. Immunol. 85 (1984) 373-383
62. Wierda W.G., Cantwell M.J., Woods S.J., Rassenti L.Z., Prussak C.E., and Kipps T.J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96 (2000) 2917-2924
63. Yellin M.J., Winikoff S., Fortune S.M., Baum D., Crow M.K., Lederman S., and Chess L. Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J. Leukocyte Biol. 58 (1995) 209-216
64. Yolcu E.S., Askenasy N., Singh N.P., Cherradi S.E., and Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 17 (2002) 795-808
65. Young L.S., Eliopoulos A.G., Gallagher N.J., and Dawson C.W. CD40 and epithelial cells: across the great divide. Immunol. Today 19 (1998) 502-506